Drugs for Aortic Valve Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 163)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Amlodipine |
Approved |
Phase 4 |
|
88150-42-9 |
2162 |
Synonyms:
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
Almirall brand OF amlodipine besilate
Amlocard
Amlodipine
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine besylate
amlodipine besylate|amlodipine maleate|Copalia® (amlodipine + valsartan)|Katerzia® (amlodipine oral suspension, 1 mg/mL)|Norvasc®|UK-4834011
Amlodipine free base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
|
Amlodipinum [Latin]
Amlodis
Amlor
AMVAZ
Astudal
ASTUDAL 5
CKD-330 COMPONENT AMLODIPINE
Coroval
Eczacibasi brand OF amlodipine besilate
HGP0904
HGP-0904
Istin
Lipinox
Lotrel
Mack brand OF amlodipine besilate
NORVAS
Norvasc
Pelmec
Pfizer brand OF amlodipine besilate
Racemic amlodipine
|
|
2 |
|
Chlorthalidone |
Approved |
Phase 4 |
|
77-36-1 |
2732 |
Synonyms:
1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-Keto-3-(3'-sulphamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulphamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulphonamide
2-Chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
2-Chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulphonamide
3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
3-(4'-Chloro-3'-sulphamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
3-Hydroxy-3-(4-chloro-3-sulphamylphenyl)phthalimidine
Chlorothalidone
Chlorphthalidolone
Chlorphthalidone
Chlortalidone
Chlortalidonum
Chlorthalidon
CHLORTHALIDONE
Clodronic Acid
|
Clortalidona
G-33182
G-33182|Hygroton®
Higroton
Hydro-Long
Hygroton
HYT182
Igroton
Isoren
Natriuran
NSC-69200
Oradil
Oxodoline
Phthalamodine
Phthalamudine
Renon
Saluretin
Tenoretic
Thalitone
Zambesil
|
|
3 |
|
Ticagrelor |
Approved |
Phase 4 |
|
274693-27-5 |
9871419 |
Synonyms:
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AR-C126532XX
AR-C126532XX|AZD6140|Brilinta®|Brilique®|compound 17 [PMID: 17827008]
AZD 6140
|
AZD6140
AZD-6140
Brilinta
Brilique
TICAGRELOR
|
|
4 |
|
Vancomycin |
Approved |
Phase 4 |
|
1404-90-6 |
14969 |
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate
(1S,2R,18R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2SP,3.5SA,2.6SP)-O(4.2),C(3.4)
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-b-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-lyxo-hexopyranosyl)-b-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-b-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
(2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
Abbott brand OF vancomycin hydrochloride
AB-vancomycin
Azupharma brand OF vancomycin hydrochloride
C(5.4),O(4.6)
Cell pharm brand OF vancomycin hydrochloride
Chiesi brand OF vancomycin hydrochloride
Combino brand OF vancomycin hydrochloride
Curasan brand OF vancomycin hydrochloride
Dakota brand OF vancomycin hydrochloride
Diatracin
Dista brand OF vancomycin hydrochloride
Eli lilly brand OF vancomycin hydrochloride
Hexal brand OF vancomycin hydrochloride
Hydrochloride, vancomycin
Lilly brand OF vancomycin hydrochloride
MIP brand OF vancomycin hydrochloride
Norman brand OF vancomycin hydrochloride
Ratiopharm brand OF vancomycin hydrochloride
|
Sulfate, vancomycin
Vanco azupharma
Vanco-cell
Vancocin
Vancocin HCL
Vancocine
VANCOLED
Vancomicin
Vancomicina
Vancomicina abbott
Vancomicina chiesi
Vancomicina combino phar
Vancomicina norman
VANCOMYCIN
Vancomycin HCL
Vancomycin hexal
Vancomycin hydrochloride
Vancomycin lilly
Vancomycin phosphate (1:2)
Vancomycin phosphate (1:2), decahydrate
Vancomycin sulfate
Vancomycine
Vancomycine dakota
Vancomycin-ratiopharm
Vancomycinum
VANCOR
Vanco-saar
|
|
5 |
|
Cefazolin |
Approved |
Phase 4 |
|
25953-19-9 |
33255 |
Synonyms:
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulphanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulphanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Ancef
Cefamedin
Cefamezin
Cefamezine
CEFAZOLIN
Cefazolin sodium
Cefazolina
Cefazoline
Cefazolinum
Cephamezine
|
Cephazolidin
Cephazolin
Cephazolin sodium
Cephazolin, sodium
Cephazoline
CEZ
Gramaxin
J01DB04
Kefzol
SK&F-41558
Sodium cephazolin
Sodium, cefazolin
Sodium, cephazolin
Totacef
|
|
6 |
|
Rivaroxaban |
Approved |
Phase 4 |
|
366789-02-8 |
9875401 |
Synonyms:
BAY 59-7939
BAY 59-7939|Xarelto®
BAY59-7939
BAY-59-7939
|
JNJ39039039
JNJ-39039039
RIVAROXABAN
XARELTO
|
|
7 |
|
Phylloquinone |
Approved, Investigational |
Phase 4 |
|
84-80-0 |
5284607 |
Synonyms:
(2S)-2-(Henicosanoyloxy)-3-(tridecanoyloxy)propyl (7Z,10Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
2',3'-trans-Vitamin K1
2’,3’-trans-vitamin K1
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
2-METHYL-3-[(2E)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-METHYL-3-[(2E,7R,11R)-3,7,11,15-TETRAMETHYLHEXADEC-2-EN-1-YL]NAPHTHALENE-1,4-DIONE
2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
2-METHYL-3-PHYTHYL-1,4-NAPHTHOCHINON
2-Methyl-3-phytyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthoquinone
2-METHYL-3-PHYTYL-1,4-NAPTHOQUINONE
3-Phytylmenadione
alpha-Phylloquinone
ANTIHEMORRHAGIC VITAMIN
a-Phylloquinone
AQUA MEPHYTON
AQUA-MEPHYTIN
Aquamephyton
COMBINAL K1
Fitomenadiona
FITOMENADIONE
KANAVIT
KATIV N
KEPHTON
KINADION
K-JECT
|
Konakion
KONAKION MM
KONAKION MM PAED
MEPHYTON
MONODION
MONO-KAY
NEOKAY
NSC-270681
ORAKAY
Phyllochinon
Phyllochinonum
Phyllohydroquinone
Phylloquinone
PHYLLOQUINONE E-FORM
PHYTHYL-MENADION
Phytomenadione
Phytomenadionum
Phytonadione
Phytonadionum
Phytylmenadione
SYNTHEX P
trans-Phylloquinone
VITAMIN K
Vitamin K 1
Vitamin K hydroquinone (phylloquinone)
Vitamin K1
Α-phylloquinone
|
|
8 |
|
Acenocoumarol |
Approved, Investigational |
Phase 4 |
|
152-72-7 |
54676537 9052 |
Synonyms:
3-(a-(4'-Nitrophenyl)-b-acetylethyl)-4-hydroxycoumarin
3-(a-(p-Nitrophenol)-b-acetylethyl)-4-hydroxycoumarin
3-(a-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
3-(a-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin
3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin
3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin
3-(a-p-Nitrophenyl-b-acetylethyl)-4-hydroxycoumarin
3-(Α-(4'-nitrophenyl)-β-acetylethyl)-4-hydroxycoumarin
3-(Α-(p-nitrophenol)-β-acetylethyl)-4-hydroxycoumarin
3-(Α-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
3-(Α-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin
3-(Α-p-nitrophenyl-β-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
Acenocoumarin
ACENOCOUMAROL
ACÉNOCOUMAROL
Acenocoumarol alliance brand
Acenocoumarol ciba-geigy brand
Acenocoumarol novartis brand
Acenocoumarolum
Acenocoumarolum [inn-latin]
Acenocumarol
Acenocumarolo
|
Acenokumarin
Alliance brand OF acenocoumarol
Ascumar
Ciba geigy brand OF acenocoumarol
Ciba-geigy brand OF acenocoumarol
Mini sintrom
Mini-sintrom
MiniSintrom
Neositron
Nicoumalone
Nicumalon
Nitrophenylacetylethyl-4-hydroxycoumarine
Nitrovarfarian
Nitrowarfarin
Novartis brand OF acenocoumarol
SIN350
Sincoumar
Sinkumar
Sinthrom
Sinthrome
Sinthrome®|Sintrom®
Sintrom
Syncoumar
Syncumar
Synthrom
Syntrom
Zotil
|
|
9 |
|
Phenprocoumon |
Approved, Investigational |
Phase 4 |
|
435-97-2 |
54680692 9908 |
Synonyms:
3-(1-Phenylpropyl)-4-hydroxycoumarin
3-(1'-Phenyl-propyl)-4-oxycoumarin
3-(a-Ethylbenzyl)-4-hydroxycoumarin
3-(alpha-Ethylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenylpropyl)-4-hydroxycoumarin
3-(a-Phenylpropyl)-4-hydroxycoumarin
3-(Α-ethylbenzyl)-4-hydroxycoumarin
3-(Α-phenylpropyl)-4-hydroxycoumarin
4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
BS-7565
Falithiom
Falithrom
Fencumar
Fenprocumon
Fenprocumone
Fenprocumone [DCIT]
Hexal brand OF phenprocoumon
|
Liquamar
Liquamar®|phenprocoumarol
Marcoumar
Marcumar
Marcuphen
Phenprocoumalol
Phenprocoumarol
Phenprocoumarole
PHENPROCOUMON
Phenprocoumone
Phenprocoumonum
Phenprocumone
Phenprogramma
Phenylpropylhydroxycumarinum
RO-1-4849
Roche brand OF phenprocoumon
Wörwag brand OF phenprocoumon
|
|
10 |
|
Dabigatran |
Approved, Investigational |
Phase 4 |
|
211914-51-1 |
216210 |
Synonyms:
BIBR 1048
BIBR-953
BIBR-953-ZW
DABIGATRAN
Dabigatran etexilate
Dabigatran etexilate mesylate
|
Etexilate mesylate, dabigatran
Etexilate, dabigatran
Mesylate, dabigatran etexilate
N-((2-(((4-(Aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine
Pradaxa
|
|
11 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
12 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
13 |
|
Oxycodone |
Approved, Illicit, Investigational |
Phase 4 |
|
76-42-6 |
5284603 |
Synonyms:
(-)-14-Hydroxydihydrocodeinone
4,5a-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5Α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
Combunox
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydrohydroxycondeinone
Dihydrone
Dihydroxycodeinone
Dinarkon
Diphydrone
Endocet
Endodan
Endone
Eubine
Eucodal
Eucodalum
Eukodal
Eutagen
IDS-NO-002
N02AA05
NSC-19043
Oxanest
Oxicodona
Oxicodona [INN-Spanish]
Oxicon
OXICONE
Oxiconum
Oxikon
Oxycodeinon
|
Oxycodeinone
Oxycodon
OXYCODONE
OXYCODONE CII
Oxycodone Hcl
Oxycodone hydrochloride
Oxycodonum
Oxycodonum [INN-Latin]
Oxycon
Oxycone
Oxycontin
OxyFAST
OxyIR
OxyNorm
Pancodine
Percobarb
Percodan
Percolone
PF-00345439
PROLADONE
PTI-821
Purdue frederick brand OF oxycodone
Remoxy
ROXICODONE
Supendol
Supeudol
Tecodin
Tekodin
Thecodine
Thekodin
Theocodin
XTAMPZA ER
|
|
14 |
|
Menadione |
Approved, Nutraceutical |
Phase 4 |
|
58-27-5 |
4055 |
Synonyms:
2-METHYL-1,4-DIHYDRONAPHTHALENE-1,4-DIONE
2-Methyl-1,4-naftochinon
2-Methyl-1,4-naphthalendione
2-Methyl-1,4-naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthodione
2-Methyl-1,4-naphthoquinone
2-Methylnaphthoquinone
3-Methyl-1,4-naphthoquinone
Aquakay
Aquinone
Bisulfite, menadione
Bisulfite, menadione sodium
Hemodal
Juva-K
Kaergona
Kanone
Kappaxan
Kappaxin
Karcon
Kareon
Kativ-g
Kayklot
Kaykot
Kaynone
Kayquinone
Kipca
Kipca-oil soluble
Klottone
Koaxin
Kolklot
|
K-Thrombyl
K-Vitan
Menadion
MENADIONE
Menadione bisulfite
Menadione sodium bisulfite
Menadione sodium bisulfite, trihydrate
Menaphthene
Menaphthon
Menaphthone
Menaphtone
Menaquinone
Menaquinone O
Mitenon
Mitenone
MNQ
NSC-4170
Panosine
Prokayvit
Sodium bisulfite, menadione
Synkay
Thyloquinone
Vicasol
Vikasol
Vitamin K 3
Vitamin K0
Vitamin K2
Vitamin K3
Vitamin K3 sodium bisulfite
Vitamin K3: 1,4-dihydro-1,4-dioxo-2-methylnaphthalene
|
|
15 |
|
Menaquinone |
Investigational |
Phase 4 |
|
1182-68-9 |
|
16 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
17 |
|
Sodium Chloride Symporter Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
19 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
20 |
|
Vitamins |
|
Phase 4 |
|
|
|
21 |
|
Trace Elements |
|
Phase 4 |
|
|
|
22 |
|
Micronutrients |
|
Phase 4 |
|
|
|
23 |
|
Factor Xa Inhibitors |
|
Phase 4 |
|
|
|
24 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
25 |
|
Serine Proteinase Inhibitors |
|
Phase 4 |
|
|
|
26 |
|
Antithrombins |
|
Phase 4 |
|
|
|
27 |
|
Antithrombin III |
|
Phase 4 |
|
|
|
28 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
29 |
|
Vitamin K |
|
Phase 4 |
|
|
|
30 |
|
Antifibrinolytic Agents |
|
Phase 4 |
|
|
|
31 |
|
Hemostatics |
|
Phase 4 |
|
|
|
32 |
|
Naphthoquinone |
|
Phase 4 |
|
|
|
Synonyms:
[1,4]Naphthoquinon
1,4-Dihydro-1,4-diketonaphthalene
1,4-Naphthalenedione
1,4-NAPHTHOQUINONE
1,4-NAPHTHO-QUINONE
1,4-NQ
alpha-Naphthoquinone
|
a-Naphthoquinone
NAPHTHALENE-1,4-DIONE
Naphthoquinone
NAPHTHOQUINONE 1
p-Naphthoquinone
Succivil
Α-naphthoquinone
|
|
33 |
|
Coagulants |
|
Phase 4 |
|
|
|
34 |
|
Cardioplegic Solutions |
|
Phase 4 |
|
|
|
35 |
|
Protamines |
|
Phase 4 |
|
|
|
36 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
37 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
38 |
|
Anesthetics |
|
Phase 4 |
|
|
|
39 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
40 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
41 |
|
Carticaine |
|
Phase 4 |
|
|
|
42 |
|
Serine |
Investigational, Nutraceutical |
Phase 4 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Î’-hydroxyalanine
Î’-hydroxy-L-alanine
|
|
43 |
|
Colchicine |
Approved |
Phase 3 |
|
64-86-8 |
2833 6167 |
Synonyms:
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
BENZO(A)HEPTALEN-9(5H)-ONE
Colchicin
Colchicina
COLCHICINE
Colchicinum
COLCRYS
Colcrys®|methoxylated analogue of XD1|XD25
COLGOUT
|
COLSALOID
CONDYLON
GLOPERBA
MITIGARE
N-(1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDROBENZO[A]HEPTALEN-7-YL)ACETAMIDE
N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO[A]HEPTALEN-7-YL)ACETAMIDE
N-ACETYLTRIMETHYLCOLCHICINIC ACID METHYL ETHER
NSC-757
|
|
44 |
|
Atorvastatin |
Approved |
Phase 3 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
45 |
|
Ezetimibe |
Approved |
Phase 3 |
|
163222-33-1 |
150311 |
Synonyms:
(1-(4-Fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
ABSORCOL
Ezedoc
Ezetimib
Ezetimiba
EZETIMIBE
ézétimibe
|
Ezetimibum
Ezetrol
MK0653
SCH 58235
SCH 58235|SCH-58235|Zetia®
SCH-58235
Zetia
|
|
46 |
|
Evolocumab |
Approved |
Phase 3 |
|
1256937-27-5 |
|
Synonyms:
AMG-145
AMG-145|AMG145|Repatha®
EVOLOCUMAB
|
REPATHA
REPATHA SURECLICK
|
|
47 |
|
Apixaban |
Approved |
Phase 3 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
48 |
|
Atenolol |
Approved |
Phase 3 |
|
29122-68-7 |
2249 |
Synonyms:
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
Aircrit
Alinor
Altol
Anselol
Antipressan
Apo-atenolol
Atcardil
Atecard
Atehexal
ATENAMIN
Atenblock
Atendol
Atenet
Ateni
Atenil
ATENIX-100
ATENIX-25
ATENIX-50
Atenol
Atenol 1a pharma
Atenol acis
Atenol al
Atenol atid
Atenol cophar
Atenol CT
Atenol fecofar
Atenol gador
Atenol genericon
Atenol GNR
Atenol heumann
Atenol MSD
Atenol NM pharma
Atenol nordic
Atenol PB
Atenol quesada
Atenol stada
Atenol tika
Atenol trom
Atenol von CT
Atenolin
Atenol-mepha
Atenolol
ATENOLOL (JAN/USP)
ATENOLOL [USAN:BAN:INN:JAN]
Atenololum
ATENOLOLUM [INN-LATIN]
Atenol-ratiopharm
Atenol-wolff
Atenomel
Atereal
Aterol
Betablok
Betacard
Betasyn
Betatop ge
Blocotenol
Blokium
C07AB03
Cardaxen
|
Cardiopress
Corotenol
Cuxanorm
Duraatenolol
Duratenol
ESATENOLOL
Evitocor
Farnormin
Felo-bits
Hipres
Hypoten
Ibinolo
ICI 66082
ICI-66082
Internolol
Jenatenol
Juvental
KENTOL
Loten
Lo-ten
Lotenal
Myocord
Myocord®|Normiten®|Tenormin®
Normalol
Normiten
Noten
Oraday
Ormidol
Panapres
Plenacor
Premorine
Prenolol
Prenormine
Prinorm
Scheinpharm atenol
Seles beta
Selobloc
Serten
Servitenol
Stermin
Tenidon
Teno-Basan
Tenobloc
Tenoblock
Tenolol
Tenoprin
Tenoretic
Tenormin
TENORMIN 25
TENORMIN L.S.
Tenormine
TENORMINE [FRENCH]
Tensimin
TOTAMOL
Tredol
Unibloc
Uniloc
VASATEN
Vascoten
Vericordin
Wesipin
Xaten
|
|
49 |
|
Telmisartan |
Approved, Investigational |
Phase 3 |
|
144701-48-4 |
65999 |
Synonyms:
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylate
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylate
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylate
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylate
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
BIBR 277
BIBR 277Se
BIBR-277
|
BIBR-277 SE
BIBR-277SE
BIBR-277-SE
BIBR-277SE|Kinzalmono®|Micardis®|Pritor®
C09CA07
Micardis
Micardis HCT
Pritor
TELMISARTAN
Telmisartan tablets
TOLURA
|
|
50 |
|
Vitamin K 1 |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 213)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement |
Unknown status |
NCT03121053 |
Phase 4 |
sodium bicarbonate;hypotone saline |
2 |
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease |
Completed |
NCT03666351 |
Phase 4 |
Amlodipine 5mg;Losartan;Losartan and Amlodipine;Amlodipine/Losartan/Chlorthalidone;current treatment |
3 |
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation |
Completed |
NCT02247128 |
Phase 4 |
Aspirin + clopidogrel;Aspirin monotherapy;OAC + clopicogrel;OAC monotherapy |
4 |
Randomized Control Study of Anticoagulation With Warfarin Por Patients With Aortic Bioprosthesis vs Aspirin Only |
Completed |
NCT03807921 |
Phase 4 |
Warfarin;Aspirin |
5 |
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial) |
Completed |
NCT02640794 |
Phase 4 |
Clopidogrel;Aspirin |
6 |
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial) |
Completed |
NCT01559298 |
Phase 4 |
Aspirin (80 mg/d) + clopidogrel (75 mg/d);Aspirin |
7 |
Effect of Pre-operative Prophylaxis With Vancomycin on Rate of Cefazolin Non-susceptible Gram Positive Surgical Site Infections in Cardiovascular Surgery Patients |
Completed |
NCT01619982 |
Phase 4 |
Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride;Cefazolin 30 mg/kg body weight |
8 |
Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) |
Recruiting |
NCT04437303 |
Phase 4 |
Continuation of oral anticoagulants;Interruption of oral anticoagulants |
9 |
Effects of Microplegia on Transfusion Rates After Cardiac Surgery: A Randomized Prospective Analysis |
Recruiting |
NCT05076604 |
Phase 4 |
Cardioplegia Solution;Microplegic Solution No. 1 |
10 |
Randomized, Evaluation of Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement |
Recruiting |
NCT04258488 |
Phase 4 |
Rivaroxaban Oral Tablet;Vitamin K antagonist(warfarin) |
11 |
An Open-label, Randomized Study of Inhibitory Effect of Evogliptin, the Dipeptidyl Peptidase-4 Inhibitor, on the Progression of Aortic Valve Calcification in Patients With Type 2 Diabetes Mellitus and Mild-to-moderate Aortic Stenosis |
Not yet recruiting |
NCT04521452 |
Phase 4 |
Evogliptin |
12 |
Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy |
Suspended |
NCT01536717 |
Phase 4 |
Articaine hydrochloride 2% solution;Sodium Chloride |
13 |
A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol |
Completed |
NCT02098772 |
Phase 3 |
Custodiol-N;Custodiol |
14 |
Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR) |
Completed |
NCT02679261 |
Phase 3 |
Atorvastatin;Placebo |
15 |
Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process |
Completed |
NCT00785109 |
Phase 3 |
|
16 |
An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS) |
Recruiting |
NCT05143177 |
Phase 2, Phase 3 |
Evogliptin;Placebo |
17 |
Does Colchicine Reduce Progression of Aortic Valve Stenosis? |
Recruiting |
NCT05162742 |
Phase 3 |
Colchicine;Placebo |
18 |
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Disease:a Prospective Randomized Controlled Trial |
Recruiting |
NCT04968509 |
Phase 3 |
PCSK9 inhibitor and Statin;Statin |
19 |
A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban |
Active, not recruiting |
NCT04142658 |
Phase 3 |
Apixaban 5 MG;Apixaban 2.5 MG;Warfarin |
20 |
A Prospective, Multi-center,Randomized Controled Trial of Sizing-strategy of Bicuspid Aortic Valve Stenosis With Transcatheter Self-expandable Valve |
Not yet recruiting |
NCT02541877 |
Phase 3 |
|
21 |
Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study) |
Terminated |
NCT01202721 |
Phase 3 |
Atenolol;Telmisartan |
22 |
Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7) |
Unknown status |
NCT03305536 |
Phase 2 |
|
23 |
Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study |
Unknown status |
NCT02917525 |
Phase 2 |
|
24 |
A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis |
Completed |
NCT02481258 |
Phase 2 |
Ataciguat (HMR1766) |
25 |
SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis |
Completed |
NCT02132026 |
Phase 2 |
Denosumab;Alendronic Acid;Denosumab Placebo;Alendronic Acid Placebo |
26 |
A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease |
Active, not recruiting |
NCT04055883 |
Phase 2 |
DA-1229 |
27 |
A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients Who Have Severe, Calcific, Bicuspid, Aortic Stenosis Requiring Aortic Valve Replacement |
Not yet recruiting |
NCT03163329 |
Phase 2 |
|
28 |
This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mechanical Aortic Heart Valve Replacement. |
Terminated |
NCT02128841 |
Phase 2 |
Rivaroxaban |
29 |
Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease |
Unknown status |
NCT00375336 |
|
|
30 |
A Pilot,Randomized Controlled-trial of Lipoprotein(a) Lowering for the Prevention of Aortic Valve Disease-translating Genomic Knowledge for Cardiovascular Prevention |
Unknown status |
NCT02109614 |
Early Phase 1 |
Extended release Niacin;Placebo Comparator |
31 |
Catheter-Based Transapical Implantation of the Ventor Embracerâ„¢ Heart Valve Prosthesis in Patients With Severe Aortic Valve Disease |
Unknown status |
NCT00677638 |
|
|
32 |
Long-Term Follow-up After the Autograft Aortic Valve Procedure (Ross Operation)-the German-Dutch- Ross Registry |
Unknown status |
NCT00708409 |
|
|
33 |
Proof of Concept of Model Based Cardiovascular Prediction |
Unknown status |
NCT02591940 |
|
|
34 |
Efficacy and Safety Evaluation for The Interventional Aortic Valve Bioprosthesis and Delivery System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation With Elevated Surgical Risk |
Unknown status |
NCT03025971 |
|
|
35 |
Spanish Percutaneous Aortic INtervention REGISTRY (SPAIN REGISTRY) |
Unknown status |
NCT04307888 |
|
|
36 |
VIenna Pilot Study for Automated Annular Suturing Technology to Assist in Aortic & Mitral Valve Replacement - A Single-center Clinical Safety & Feasibility Pilot Trial |
Unknown status |
NCT04659655 |
|
|
37 |
Registry Study of Aortic Valve Diseases in Chinese Elderly |
Unknown status |
NCT02623907 |
|
|
38 |
Feasibility of Delivering Enhanced Recovery After Cardiac Surgery |
Unknown status |
NCT03859102 |
|
Oral Gabapentin pre-op;Oral Lansoprazole pre-op;Intravenous Paracetamol intra-operatively;Intravenous Dexamethasone intra-operatively;Intravenous Ondansetron intra-operatively;Infiltration of surgical wounds with local anaesthetic;Intravenous Magnesium intra-operatively;Post-operative Gabapentin analgesia;Post-operative oral Paracetamol analgesia;Post-operative Ondansetron anti-emesis |
39 |
Impact of Anesthesia Technique on Post-operative Delirium After Transcatheter Aortic Valve Implantation |
Unknown status |
NCT03323619 |
|
|
40 |
Smart - Systems Medicine of Heart Failure |
Unknown status |
NCT03172338 |
|
|
41 |
Early Outcomes of Concomitant Transcatheter Aortic Valve Implantation and Off-pump Coronary Artery Bypass Grafting in Management of Severe Symptomatic Aortic Stenosis and Coronary Artery Disease |
Unknown status |
NCT04525339 |
|
|
42 |
Clinical Evaluation of the Safety and Performance of the MicroPort's Transcatheter Aortic Valve and Delivery System for Treatment of Severe Aortic Stenosis |
Unknown status |
NCT02221921 |
|
|
43 |
Aortic Valve Dynamics During Exercise After Valve Sparing Root Replacement Surgery |
Unknown status |
NCT04205474 |
|
|
44 |
BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience. |
Unknown status |
NCT03495050 |
|
|
45 |
Whole Exome Sequencing in Bicuspid Aortic Valve Patients |
Unknown status |
NCT02899624 |
|
|
46 |
Bicuspid aoRtic vAlVe gEnetic Research - BRAVE Study |
Unknown status |
NCT04514445 |
|
|
47 |
Clinical Evaluation of the Safety and Performance of Percutaneous Implantation of the Venus MedTech Aortic Valve Prosthesis for Patients Who Cannot Undergo Surgical Valve Replacement |
Unknown status |
NCT01683474 |
|
|
48 |
Left Ventricular Reverse Remodeling in Aortic Valve Replacement With Single Strip Pericardium and Mechanical Valve: A Comparative Study |
Unknown status |
NCT04056832 |
|
|
49 |
Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD |
Unknown status |
NCT02516800 |
|
|
50 |
Accuracy of Using 2D Transesophageal Echocardiography Compared to Balloon Sizing in Determining Valve Size During Transcatheter Aortic Valve Implantation |
Unknown status |
NCT04242225 |
|
|
|